We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+43.68%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.35B
AUM Growth
+$397M
Cap. Flow
+$106M
Cap. Flow %
7.83%
Top 10 Hldgs %
60.29%
Holding
72
New
21
Increased
13
Reduced
7
Closed
23
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$84.3M
2
XNCR icon
Xencor
XNCR
+$62.7M
3
RNAM
Avidity Biosciences
RNAM
+$60.7M
4
AKUS
Akouos Inc
AKUS
+$44M
5
RCUS icon
Arcus Biosciences
RCUS
+$41M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$61.6M
2
FATE icon
Fate Therapeutics
FATE
+$51.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45M
4
KYNB icon
Kyntra Bio
KYNB
+$30.7M
5
IPHA icon
Innate Pharma
IPHA
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Miscellaneous 2.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNCR icon
1
Xencor
XNCR
$1.74B
$147M 10.88%
4,547,072
+2,045,515
+82% +$62.7M
2018 Q4
6 quarters
PRTA icon
2
Prothena Corp
PRTA
$430M
$98.6M 7.28%
9,426,640
– –
2018 Q4
6 quarters
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.2B
$89.1M 6.58%
+2,642,218
New +$84.3M
2020 Q2
0 quarters
MORF icon
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$76.8M 5.67%
2,837,973
+14,832
+0.5% +$278K
2019 Q2
4 quarters
KURA icon
5
Kura Oncology
KURA
$855M
$75.1M 5.55%
4,608,529
+1,096,839
+31% +$15.8M
2015 Q4
18 quarters
ASMB icon
6
Assembly Biosciences
ASMB
$418M
$73.5M 5.43%
262,816
+46,926
+22% +$10.9M
2019 Q3
3 quarters
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$69.1M 5.11%
2,721,993
-624,308
-19% -$13.4M
2017 Q1
13 quarters
ANAB icon
8
AnaptysBio
ANAB
$1.4B
$68.7M 5.07%
3,075,014
+39,000
+1% +$713K
2019 Q4
2 quarters
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$59.5M 4.39%
+2,103,950
New +$60.7M
2020 Q2
0 quarters
NGNE icon
10
Neurogene
NGNE
$444M
$58.7M 4.34%
176,834
-7,826
-4% -$2.04M
2018 Q2
8 quarters
RCUS icon
11
Arcus Biosciences
RCUS
$2.87B
$44.8M 3.31%
1,810,000
+1,517,900
+520% +$41M
2018 Q1
9 quarters
AKUS
12
DELISTED
Akouos Inc
AKUS
$44.5M 3.28%
+1,975,984
New +$44M
2020 Q2
0 quarters
GERN icon
13
Geron
GERN
$765M
$41.9M 3.1%
+19,230,769
New +$28.7M
2020 Q2
0 quarters
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$40.9M 3.02%
357,849
– –
2018 Q4
6 quarters
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$1.47B
$40.6M 3%
519,119
+147,911
+40% +$9.79M
2019 Q1
5 quarters
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$33M 2.44%
5,033,861
+3,759,398
+295% +$13.6M
2018 Q2
8 quarters
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$31.7M 2.34%
1,489,185
+383,005
+35% +$6.77M
2019 Q2
4 quarters
AMTI
18
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$28.9M 2.14%
+1,150,000
New +$29M
2020 Q2
0 quarters
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$25.2M 1.86%
+837,885
New +$30.2M
2020 Q2
0 quarters
FATE icon
20
Fate Therapeutics
FATE
$232M
$21.3M 1.57%
619,855
-1,722,020
-74% -$51.3M
2019 Q4
2 quarters
DNLI icon
21
Denali Therapeutics
DNLI
$2.86B
$17.7M 1.31%
733,561
+35,460
+5% +$834K
2020 Q1
1 quarter
BMY.RT icon
22
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$17M 1.26%
4,748,300
+2,500,000
+111% +$9.02M
2020 Q1
1 quarter
KRSA
23
Korsana Biosciences, Inc. Common Stock
KRSA
$1.56B
$16.2M 1.2%
19,588
– –
2019 Q2
4 quarters
FULC icon
24
Fulcrum Therapeutics
FULC
$280M
$16.1M 1.19%
+882,353
New +$13.9M
2020 Q2
0 quarters
CRNX icon
25
DELISTED
Crinetics Pharmaceuticals
CRNX
$15.1M 1.11%
859,802
+509,802
+146% +$8.69M
2020 Q1
1 quarter
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2020 Portfolio in Review

As of Q2 2020, EcoR1 Capital held 72 positions worth $1.35B, up 41% from $957M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2020, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $51.3M trimmed.

  • EcoR1 Capital's largest Q2 2020 buy was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.
  • EcoR1 Capital added most to Xencor in Q2 2020, an estimated $62.7M increase.
  • EcoR1 Capital's biggest Q2 2020 reduction was Fate Therapeutics, cutting an estimated $51.3M.
  • EcoR1 Capital fully exited Arvinas in Q2 2020, selling an estimated $61.6M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.35B portfolio in Q2 2020.
  • EcoR1 Capital opened 21 new positions and closed 23 in Q2 2020.
  • EcoR1 Capital's portfolio value rose 41% quarter-over-quarter to $1.35B.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.